PR Newswire·Nov 9, 2026, 7:30 AM ET

ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates

ADCT

ADC Therapeutics reported third quarter 2026 net product revenue of $21 million & cash & cash equivalents of $189.2 million as of September 30, 2026.
A strategic financial restructuring completed in October 2026 included an $86.6 million PIPE financing & amendments to debt agreements, extending the expected cash runway into 2029.
Multiple abstracts for ZYNLONTA were accepted for presentation at ASH 2026, including full results from the Phase 3 LOTIS-5 trial & Phase 1b LOTIS-7 trial data.
Tanabe Pharma submitted a marketing authorization application for ZYNLONTA in Japan & entered an exclusive sublicensing agreement with Nippon Shinyaku for commercialization.
Net product revenues increased to $21.0 million for the quarter from $15.8 million in the prior year period, driven primarily by volume growth.
Research & development expenses decreased to $14.7 million for the quarter from $26.8 million in the prior year period due to reduced spending on discontinued programs & lower ZYNLONTA costs.
Total operating expenses decreased by 24% to $36.1 million for the quarter, while adjusted net loss narrowed to $8.8 million from $25.5 million in the prior year period.
The company recognized $0.1 million in expense reversals related to restructuring costs for the quarter & $2.6 million in severance costs for the nine-month period.
Share-based compensation expense was $4.1 million for the quarter, representing a 105% increase compared to the prior year period.
Adjusted total operating expenses for the nine-month period decreased by 21% to $112.1 million, primarily driven by lower R&D expenses.
Net loss per share was $0.16 for the quarter, compared to $0.30 in the prior year period, while adjusted net loss per share was $0.06 compared to $0.19 previously.
ZYNLONTA remains approved by the FDA & European Commission for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Company: ADC Therapeutics SA
Keywords: ADC Therapeutics SA